Adjuvant Tx HER2 Negative EBC
Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool

Released: August 22, 2024

Expiration: August 21, 2025

About This Tool

Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool

Clinical Care Options, LLC, is grateful to Kevin Kalinsky, MD, MS; Laura A. Huppert, MD; Reshma L. Mahtani, DO; Laura M. Spring, MD; and Tiffany A. Traina, MD, FASCO, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in August 2024 and reflects the experts’ recommendations at that time.

The goal of the tool is to educate healthcare professionals on making optimal adjuvant therapy choices for patients with HER2-negative early breast cancer who have already undergone surgery and, if applicable, are already receiving adjuvant endocrine therapy.

A series of questions allows the user to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include hormone receptor status, germline BRCA mutation status, and eligibility for pivotal phase III trials, among other factors.

It should be noted that these are not exclusive characteristics when selecting optimal adjuvant therapy for patients with HER2-negative early breast cancer. Other considerations that are not included in this tool—such as the presence of various comorbidities that could preclude use of pembrolizumab (eg, severe autoimmune disease) or abemaciclib (eg, severe ulcerative colitis or Crohn’s disease)—also should be considered, when feasible/appropriate.

This tool assumes the patient is a “standard” adult diagnosed with HER2-negative early breast cancer who has undergone surgery and, if applicable, is already receiving adjuvant endocrine therapy, but who has no additional features or specific comorbidities that would affect treatment choice other than those described when entering the patient details. Based on the characteristics entered, the tool will display expert recommendations for that specific patient case.

For additional information on best practices in multidisciplinary care of patients with HER2-negative early breast cancer, please see our online program featuring a series of modules and accompanying downloadable slidesets. Topics include:

  • Integrating adjuvant CDK4/6 inhibitors into care of HR-positive/HER2-negative early breast cancer
  • Germline BRCA testing and targeting in HER2-negative early breast cancer
  • Immune checkpoint inhibitor therapy for HER2-negative early breast cancer

This program is supported by educational grants from AstraZeneca; Merck Sharp & Dohme, LLC; and Novartis Pharmaceuticals Corporation.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

Laura A. Huppert, MD: consultant/advisor/speaker: AstraZeneca, Pfizer.

Kevin Kalinsky, MD, MS: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genentech/Roche, Immunomedics, Menarini, Mersana, Merck, Myovant, Puma Technology, Seattle Genetics, Silicon Biosystems, Takeda.

Reshma Mahtani, DO: consultant/advisor: Agendia, Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Genentech, Gilead, Hologic, Lilly, Merck, Novartis, Pfizer, Puma, Sanofi, Seagen, Sermonix, Stemline.

Laura M. Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Precede, Seagen; researcher: Genentech, Gilead, Lilly, Merck.

Tiffany A. Traina, MD, FASCO: consultant/advisor: AstraZeneca, BioTheranostics, Daiichi Sankyo, Exact Sciences, G1 Therapeutics, GE Healthcare, Genentech/Roche, Gilead, GlaxoSmithKline, Hengrui, Merck, Novartis, Pfizer, Stemline, TerSera; researcher (paid to institution): Astellas, AstraZeneca, Ayala, Daiichi Sankyo, Genentech/Roche, Pfizer.

© 2024 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal adjuvant therapy choices for treating individuals with HER2-negative early breast cancer who have already undergone surgery and, if applicable, are already receiving adjuvant endocrine therapy. The information provided is based on the expert guidance of Kevin Kalinsky, MD, MS; Laura A. Huppert, MD; Reshma L. Mahtani, DO; Laura M. Spring, MD; and Tiffany A. Traina, MD, FASCO.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options, including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights, are disclaimed.

Any trademarks are the property of respective companies.

© 2024 Clinical Care Options, LLC. All rights reserved.

Program Content